This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's 'Mad Money' Recap: Surprise! It's a Rally

Finally, there's Q2 Holdings, which will sport the ticker "QTWO." Cramer said this company offers online banking services to 334 smaller banks and expects to price its shares between $11 and $13 a share.

Cramer said he's not a fan of some other upcoming cloud IPOs, including A10 Networks, Amber Road and BorderFree.

Biotechs on the IPO Trail

Continuing with his IPO theme, Cramer highlighted another coming initial public offering, this time in the red-hot biotech segment. There have been four biotech IPOs since January that have more than doubled, Cramer noted. While this does represent froth in the markets, why not take advantage of it in the short-term while the trend continues?

The company is MediWound, which will trade as "MDWD" when it debuts. Cramer said this Israeli company is developing a drug to remove dead tissue from burn victims, tissue that would have to be surgically removed otherwise. While only in Phase II testing, the drug represents a huge step forward and, thanks to orphan drug status, will have little competition.

Must Read: Jim Cramer's 'Mad Money' Recap: Lost in the Rotation

MediWound is a tiny deal, pricing between $14 and $16 a share for a valuation of just $306 million. Cramer said he's recommending this as a trade off the IPO and not as a longer-term investment. The company doesn't expect any profits until 2018.

Other biotech IPOs that caught Cramer's eye are Akebia Therapeutics and Versartis, but he remains most excited about MediWound.

Lightning Round

In the Lightning Round, Cramer was bullish on Kate Spade (KATE), Pengrowth Energy Trust (PGH), Zulily (ZU) and American International Group (AIG).

Cramer was bearish on Prospect Capital (PSEC).

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GTAT $0.50 -2.08%
INCY $72.38 -1.10%
SUNE $0.24 -3.25%
AAPL $95.03 -2.90%
FB $117.52 7.90%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs